Rosemarie De Haan
Ph.D. student
Department of Cancer
Netherlands Cancer Institute
Netherlands
Biography
Her PhD project involves clinical and translational research. The main goal is to determine the safety and tolerability of olaparib (a PARP inhibitor) combined with radiotherapy in different groups of patients: non-small-cell lung cancer, head and neck squamous cell carcinoma and breast cancer patients. PARP is involved in single strand DNA repair. PARP inhibition leads to radiosensitization through the conversion of irradiation induced single strand DNA breaks into for the cell lethal double strand DNA breaks upon replication.
Research Interest
The translational research includes pharmacokinetic and pharmacodynamic analysis within the trial; as well as some in vitro cell culture studies.
